Peramivir Trihydrate

製品コードS2716 バッチS271601

印刷

化学情報

Synonyms

BCX-1812, RWJ-270201, S-021812

Storage
(From the date of receipt)

3 years -20°C powder
1 years -80°C in solvent

化学式

C₁₅H₂₈N₄O₄.3H₂O

分子量

382.45

CAS No.

1041434-82-5

Solubility (25°C)*

体外

5%TFA

3 mg/mL (7.84 mM)

DMSO

0.2 mg/mL (0.52 mM)

Water

Insoluble

体内（毎回新しく調製した物を用意してください）

Clear solution

5%TFA 1 40%PEG300 2 5%Tween80 3 50%ddH2O

この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。

0.15mg/ml (0.39mM)

Taking the 1 mL working solution as an example, add 50 μL of 3 mg/ml clarified TFA stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Peramivir Trihydrate（BCX-1812、RWJ-270201、S-021812）は、抗感染症薬ペラミビルの三水和物で、これは遷移状態アナログであり、強力で特異的なInfluenza Virus Neuraminidase阻害剤であり、IC50中央値は0.09 nMです。
in vivo	Peramivir protects mice against severe disease outcomes following infection with highly pathogenic avian influenza and multi-dose treatment was efficacious in ferrets. Peramivir combined with Oseltamivir perform better than suboptimal doses of each compound alone to treat influenza infections in mice. Peramivir (30 mg/kg) is effective in promoting the survival of mice infected with systemically replicating H5N1 virus. Peramivir is 30% protective against H1N1 virus in mice at 0.5 mg/kg/d, but ineffective at lower doses when used as monotherapy. Peramivir combined with favipiravir increases the numbers of survivors by 10-50% when the 0.025 mg/kg/d, 0.05 mg/kg/d, and 0.1 mg/kg/d doses of Peramivir are combined with 20 mg/kg/d Favipiravir and when all doses of Peramivir are combined with 40 mg/kg/d Favipiravir. Peramivir combined with favipiravir results in an increase in lifespan, improved body weight and significant reductions in lung hemorrhage score and lung weight in H1N1 infected mice. Peramivir (1 mg/kg/d) combined with Rimantadine (5 mg/kg/d and 10 mg/kg/d) produces weight losses of 1.69 and 0.69, respectively, whereas the combination of 3.0 mg/kg/d Peramivir with 10 and 30 mg/kg/d Rimantadine does not show any weight loss in sub-lethal influenza A (H3N2) virus mouse model.

製品説明

Peramivir Trihydrate（BCX-1812、RWJ-270201、S-021812）は、抗感染症薬ペラミビルの三水和物で、これは遷移状態アナログであり、強力で特異的なInfluenza Virus Neuraminidase阻害剤であり、IC50中央値は0.09 nMです。

in vivo

Peramivir protects mice against severe disease outcomes following infection with highly pathogenic avian influenza and multi-dose treatment was efficacious in ferrets. Peramivir combined with Oseltamivir perform better than suboptimal doses of each compound alone to treat influenza infections in mice. Peramivir (30 mg/kg) is effective in promoting the survival of mice infected with systemically replicating H5N1 virus. Peramivir is 30% protective against H1N1 virus in mice at 0.5 mg/kg/d, but ineffective at lower doses when used as monotherapy. Peramivir combined with favipiravir increases the numbers of survivors by 10-50% when the 0.025 mg/kg/d, 0.05 mg/kg/d, and 0.1 mg/kg/d doses of Peramivir are combined with 20 mg/kg/d Favipiravir and when all doses of Peramivir are combined with 40 mg/kg/d Favipiravir. Peramivir combined with favipiravir results in an increase in lifespan, improved body weight and significant reductions in lung hemorrhage score and lung weight in H1N1 infected mice. Peramivir (1 mg/kg/d) combined with Rimantadine (5 mg/kg/d and 10 mg/kg/d) produces weight losses of 1.69 and 0.69, respectively, whereas the combination of 3.0 mg/kg/d Peramivir with 10 and 30 mg/kg/d Rimantadine does not show any weight loss in sub-lethal influenza A (H3N2) virus mouse model.

プロトコル(参考用のみ)

参考

https://pubmed.ncbi.nlm.nih.gov/18234269/
https://pubmed.ncbi.nlm.nih.gov/20633577/
https://pubmed.ncbi.nlm.nih.gov/18573280/

https://pubmed.ncbi.nlm.nih.gov/22429564/
https://pubmed.ncbi.nlm.nih.gov/20943201/

+ 展开

カスタマーフィードバック

: , , Emerg Microbes Infect, 2014, 3(11): e78.

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro [ Viruses, 2024, 16(9)1467]	PubMed: 39339943
Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution. [ Emerg Microbes Infect, 2014, 3(11):e78]	PubMed: 26038501
Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution. [Zhang XN, et al. Emerg Microbes Infec, 2014, 3, e78]

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。